CONTROL BIONICS LIMITED — Capital/Financing Update 2025

Dec 30, 2025

==> picture [145 x 45] intentionally omitted <==

31 December 2025

Control Bionics Completes Acquisition of Neuro Elite Athletics (NeuroBounce)

Melbourne, Australia – Control Bionics Limited (ASX: CBL) (“Control Bionics” or the “Company”) is pleased to announce that it has completed the acquisition of 100% of Neuro Elite Athletics LLC, the U.S. company behind the NeuroBounce athletic performance program.

This announcement follows the Company’s prior ASX announcement on 3 December 2025 which outlined the proposed acquisition.

Completion occurred on 31 December 2025, with Control Bionics’ U.S. subsidiary, Control Bionics Ngage Inc., acquiring the remaining ownership interests in Neuro Elite Athletics LLC, resulting in Neuro Elite Athletics becoming a wholly owned subsidiary of Control Bionics.

Final Consideration and Funding

The final consideration was US$370,028, which was satisfied through the issue of 8,443,747 ordinary fully paid shares in Control Bionics at an issue price of A$0.0653 per share.

The shares were issued under the Company’s existing placement capacity pursuant to ASX Listing Rule 7.1. No shareholder approval was required.

Strategic Rationale

The acquisition enables integration of the NeuroBounce performance program with Control Bionics’ NeuroStrip EMG technology platform, supporting the Company’s strategy to expand into high-growth sports performance and human optimisation markets, while leveraging its deep expertise in surface electromyography (EMG).

With full ownership now secured, Control Bionics will integrate Neuro Elite Athletics’ intellectual property, brand, customers and operational capabilities into the broader Control Bionics group.

Management Commentary

Jeremy Steele, CEO and Managing Director of Control Bionics, said:

“The completion of the Neuro Elite Athletics acquisition marks an important milestone for Control Bionics. NeuroBounce has demonstrated strong early traction, and full ownership allows us to accelerate integration with NeuroStrip, expand commercial partnerships and pursue growth opportunities across elite sport, return-to-play and performance optimisation markets in the U.S. and Australia.”

Steve Bennett, Founder of Neuro Elite Athletics, said:

“This transaction represents the natural evolution of a long-standing and highly aligned partnership. NeuroBounce and Control Bionics share a commitment to evidence-based, performance-driven technology, and bringing our two 20-year-old businesses together creates a powerful platform for

Control Bionics Limited Registered Office: Level 4, 11-13 Pearson Street, Cremorne, Victoria, 3121, Australia T: +61 3 9897 3576 W: www.controlbionics.com ABN: 45 115 465 462

innovation and growth. I’m excited to continue working with the Control Bionics team as we scale NeuroBounce globally.”

Authorisation

This ASX announcement has been approved for release by the CEO of Control Bionics Limited.

For further information, please contact:

Investors and Media Jeremy Steele – CEO & Managing Director jsteele@controlbionics.com

Brett Crowley – Company Secretary brettcrowley@controlbionics.com

For further information visit the website: https://www.controlbionics.com/

About Control Bionics:

Control Bionics is a medical device company that has more than 20 years’ experience in the development and use of surface Electromyography (EMG) devices.

About NeuroNode:

Our core patented NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as EMG output. This output is then sent wirelessly via the NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Our technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse, and the NeuroNode acts as like the mouse button. Control Bionics is the only such product to harness three modalities – touch, eye and NeuroNode control – which combined yield unique benefits in terms of the ability of patients to express themselves with significantly faster speed and less fatigue.

About NeuroStrip:

Control Bionics is currently commercialising its most recent advancement in its technology, the NeuroStrip. This wearable, miniaturised EMG device provides the business with the opportunity to enter new markets such as health diagnostics, sports performance and rehabilitation to name only a few potential markets.

Control Bionics operates in North America, Australia, Singapore and Japan.

Control Bionics Limited Registered Office: Level 4, 11-13 Pearson Street, Cremorne, Victoria, 3121, Australia T: +61 3 9897 3576 W: www.controlbionics.com ABN: 45 115 465 462